{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:32:49Z","timestamp":1793392369014,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40263-013-0115-5","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T15:02:07Z","timestamp":1381330927000},"page":"1069-1080","source":"Crossref","is-referenced-by-count":96,"title":["Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor"],"prefix":"10.1007","volume":"27","author":[{"given":"Katrina","family":"Weston-Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,10]]},"reference":[{"key":"115_CR1","doi-asserted-by":"crossref","unstructured":"Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006. 2006(Issue 1):Art. No.: CD003476. doi: 10.1002\/14651858.CD003476.pub2 .","DOI":"10.1002\/14651858.CD003476.pub2"},{"issue":"4","key":"115_CR2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.psyneuen.2007.02.005","volume":"32","author":"F Brambilla","year":"2007","unstructured":"Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: Involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402\u20136.","journal-title":"Psychoneuroendocrinology"},{"issue":"19","key":"115_CR3","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8190","volume":"8","author":"C Bridle","year":"2004","unstructured":"Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2004;8(19):iii\u2013iv.","journal-title":"Health Technol Assess"},{"issue":"4","key":"115_CR4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"C Budman","year":"2001","unstructured":"Budman C, Gayer A, Lesser M, Shi Q, Bruun R. An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry. 2001;62(4):290\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"115_CR5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1176\/appi.ajp.159.11.1932","volume":"159","author":"F Centorrino","year":"2002","unstructured":"Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, Salvatore P, et al. Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989. Am J Psychiatry. 2002;159(11):1932\u20135.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"115_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M Hert De","year":"2011","unstructured":"De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144\u201358.","journal-title":"Eur Psychiatry"},{"issue":"3","key":"115_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00002512-200522030-00006","volume":"22","author":"IB Frenchman","year":"2005","unstructured":"Frenchman IB. Atypical antipsychotics for nursing home patients: a retrospective chart review. Drugs Aging. 2005;22(3):257\u201364.","journal-title":"Drugs Aging"},{"issue":"9","key":"115_CR8","doi-asserted-by":"crossref","first-page":"e3150","DOI":"10.1371\/journal.pone.0003150","volume":"3","author":"D Pickar","year":"2008","unstructured":"Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One. 2008;3(9):e3150.","journal-title":"PLoS One"},{"issue":"8","key":"115_CR9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","volume":"21","author":"A Zuddas","year":"2011","unstructured":"Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21(8):600\u201320.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"115_CR10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0885-3924(02)00378-0","volume":"23","author":"N Khojainova","year":"2002","unstructured":"Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. J Pain Symptom Manage. 2002;23(4):346\u201350.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"115_CR11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpainsymman.2010.02.017","volume":"40","author":"A Elsayem","year":"2010","unstructured":"Elsayem A, Bush SH, Munsell MF, Curry Iii E, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manage. 2010;40(5):774\u201382.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"115_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.1999.tb10908.x","volume":"100","author":"T Baptista","year":"1999","unstructured":"Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100(1):3\u201316.","journal-title":"Acta Psychiatr Scand"},{"key":"115_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"J Newcomer","year":"2005","unstructured":"Newcomer J. Second-generation atypical antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs. 2005;19:1\u201393.","journal-title":"CNS Drugs"},{"issue":"12","key":"115_CR14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. The clinical antipsychotic trials of intervention effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"issue":"3, Suppl. 1","key":"115_CR15","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2007.01.003","volume":"120","author":"DJ Rader","year":"2007","unstructured":"Rader DJ. Effect of insulin resistance, dyslipidemia, and Intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120(3, Suppl. 1):S12\u20138.","journal-title":"Am J Med"},{"issue":"3","key":"115_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","volume":"119","author":"SM Stahl","year":"2009","unstructured":"Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"115_CR17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, Obesity NAAftSo","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, Obesity NAAftSo. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596\u2013601.","journal-title":"Diabetes Care"},{"issue":"5","key":"115_CR18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","volume":"34","author":"P Oriot","year":"2008","unstructured":"Oriot P, Feys J, Mertens de Wilmars S, Misson S, Ayache A, Fagnart O, et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. 2008;34(5):490\u20136.","journal-title":"Diabetes Metab"},{"issue":"5","key":"115_CR19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.pnpbp.2006.02.007","volume":"30","author":"MT Lambert","year":"2006","unstructured":"Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(5):919\u201323.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"115_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","volume":"28","author":"R Perez-Iglesias","year":"2008","unstructured":"Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Teran JM, et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1\u00a0year of treatment. J Clin Psychopharmacol. 2008;28(3):289\u201395.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"115_CR21","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","volume":"33","author":"J Sacher","year":"2008","unstructured":"Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology. 2008;33(7):1633\u201341.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"115_CR22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","volume":"165","author":"R Wu","year":"2008","unstructured":"Wu R, Zhao J, Guo X, He Y, Fang M, Guo W, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352\u20138.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"115_CR23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","volume":"16","author":"VL Albaugh","year":"2010","unstructured":"Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2010;16(5):569\u201381.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"115_CR24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbr.2010.08.046","volume":"216","author":"M Shobo","year":"2010","unstructured":"Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, et al. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res. 2010;216(2):561\u20138.","journal-title":"Behav Brain Res"},{"issue":"6","key":"115_CR25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","volume":"34","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TKY, Pang CC, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):945\u201354.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1\u20133","key":"115_CR26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","volume":"108","author":"AF Chintoh","year":"2009","unstructured":"Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108(1\u20133):127\u201333.","journal-title":"Schizophr Res"},{"issue":"6","key":"115_CR27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","volume":"29","author":"R Coccurello","year":"2009","unstructured":"Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, et al. 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. J Clin Psychopharmacol. 2009;29(6):576\u201383.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"115_CR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000285780","volume":"61","author":"S Park","year":"2010","unstructured":"Park S, Hong S, Ahn I, Kim D, Kim S. Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats. Neuropsychobiology. 2010;61(3):148.","journal-title":"Neuropsychobiology"},{"issue":"1","key":"115_CR29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2010.05.009","volume":"97","author":"EM Zwaal van der","year":"2010","unstructured":"van der Zwaal EM, Luijendijk MCM, Evers SS, la Fleur SE, Adan RAH. Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav. 2010;97(1):130\u20137.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"115_CR30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","volume":"217","author":"K Weston-Green","year":"2011","unstructured":"Weston-Green K, Huang X-F, Deng C. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res. 2011;217(2):337\u201346.","journal-title":"Behav Brain Res"},{"issue":"2","key":"115_CR31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000100981","volume":"85","author":"G Tulipano","year":"2007","unstructured":"Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology. 2007;85(2):61.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"115_CR32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","volume":"31","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci. 2010;31(10):484\u201397.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"115_CR33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","volume":"127","author":"R Coccurello","year":"2010","unstructured":"Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210\u201351.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"115_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","volume":"32","author":"KL Houseknecht","year":"2006","unstructured":"Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2006;32(2):289\u201397.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"115_CR35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","volume":"28","author":"AF Chintoh","year":"2008","unstructured":"Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 2008;28(5):494\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"115_CR36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(01)01000-2","volume":"111","author":"E Koller","year":"2001","unstructured":"Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111(9):716\u201323.","journal-title":"Am J Med"},{"key":"115_CR37","doi-asserted-by":"crossref","unstructured":"Strassnig M, Awerbuck J, Ganguli R. Diabetes resolution following discontinuation of a second-generation antipsychotic: three cases. Clin Schizophrenia Relat Psychoses. 2012;6(4):202\u20133.","DOI":"10.3371\/CSRP.STAW.01062013"},{"issue":"3","key":"115_CR38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","volume":"62","author":"HN Boyda","year":"2012","unstructured":"Boyda HN, Procyshyn RM, Tse L, Wong D, Pang CC, Honer WG, et al. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology. 2012;62(3):1391\u2013400.","journal-title":"Neuropharmacology"},{"issue":"5","key":"115_CR39","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","volume":"54","author":"DE Johnson","year":"2005","unstructured":"Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 2005;54(5):1552\u20138.","journal-title":"Diabetes"},{"issue":"5","key":"115_CR40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","volume":"26","author":"C Chiu","year":"2006","unstructured":"Chiu C, Chen K, Liu H, Lu M. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol. 2006;26(5):504\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"115_CR41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","volume":"34","author":"C-C Chiu","year":"2010","unstructured":"Chiu C-C, Chen C-H, Chen B-Y, Yu S-H, Lu M-L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):866\u201370.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"115_CR42","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jc.87.6.2918","volume":"87","author":"MO Sowell","year":"2002","unstructured":"Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87(6):2918\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"115_CR43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/dc06-1063","volume":"30","author":"TA Hardy","year":"2007","unstructured":"Hardy TA, Meyers AL, Yu J, Shankar SS, Steinberg HO, Porksen NK. Acute insulin response and \u03b2-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks. Diabetes Care. 2007;30(1):157\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"115_CR44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","volume":"54","author":"M Ader","year":"2005","unstructured":"Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54(3):862\u201371.","journal-title":"Diabetes"},{"issue":"8","key":"115_CR45","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","volume":"6","author":"VL Albaugh","year":"2011","unstructured":"Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6(8):e22662.","journal-title":"PLoS One"},{"issue":"9","key":"115_CR46","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","volume":"62","author":"KL Teff","year":"2013","unstructured":"Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232\u201340.","journal-title":"Diabetes"},{"issue":"4","key":"115_CR47","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1530\/acta.0.0830772","volume":"83","author":"JR Henderson","year":"1976","unstructured":"Henderson JR, Jefferys DB, Jones RH, Stanley D. The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects. Acta Endocrinol (Cph). 1976;83(4):772\u201380.","journal-title":"Acta Endocrinol (Cph)"},{"issue":"1\u20132","key":"115_CR48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-1838(95)00101-8","volume":"57","author":"H Ohnuma","year":"1996","unstructured":"Ohnuma H, Yamatani K, Igarashi M, Sugiyama K, Manaka H, Tominaga M, Sasaki H. Intracerebroventricular injection of methylatropine suppresses insulin-response to oral glucose-load in rats. J Auton Nerv Syst. 1996;57(1\u20132):43\u20138.","journal-title":"J Auton Nerv Syst"},{"issue":"2","key":"115_CR49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/eje.0.1500097","volume":"150","author":"B Ahren","year":"2004","unstructured":"Ahren B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol. 2004;150(2):97\u2013104.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"115_CR50","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1210\/jc.87.6.2899","volume":"87","author":"GI Uwaifo","year":"2002","unstructured":"Uwaifo GI, Parikh SJ, Keil M, Elberg J, Chin J, Yanovski JA. Comparison of insulin sensitivity, clearance, and secretion estimates using euglycemic and hyperglycemic clamps in children. J Clin Endocrinol Metab. 2002;87(6):2899\u2013905.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"115_CR51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0924-977X(03)00072-5","volume":"14","author":"K Melkersson","year":"2004","unstructured":"Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol. 2004;14(2):115\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"115_CR52","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1007\/s00125-006-0446-6","volume":"49","author":"N Sasaki","year":"2006","unstructured":"Sasaki N, Iwase M, Uchizono Y, Nakamura U, Imoto H, Abe S, et al. The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia. 2006;49(12):2930\u20138.","journal-title":"Diabetologia"},{"issue":"12","key":"115_CR53","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","volume":"51","author":"G Smith","year":"2008","unstructured":"Smith G, Chaussade C, Vickers M, Jensen J, Shepherd P. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia. 2008;51(12):2309\u201317.","journal-title":"Diabetologia"},{"issue":"2\u20133","key":"115_CR54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.schres.2012.11.016","volume":"143","author":"P Manu","year":"2013","unstructured":"Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Shiffeldrim D, et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013;143(2\u20133):358\u201362.","journal-title":"Schizophr Res"},{"issue":"5","key":"115_CR55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/er.2003-0026","volume":"25","author":"C Bouche","year":"2004","unstructured":"Bouche C, Serdy S, Kahn CR, Goldfine AB. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev. 2004;25(5):807\u201330.","journal-title":"Endocr Rev"},{"issue":"Suppl. 3","key":"115_CR56","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S1262-3636(10)70466-3","volume":"36","author":"B Thorens","year":"2010","unstructured":"Thorens B. Central control of glucose homeostasis: the brain\u2014endocrine pancreas axis. Diabetes Metab. 2010;36(Suppl. 3):S45\u20139.","journal-title":"Diabetes Metab"},{"issue":"10","key":"115_CR57","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.2337\/db07-1788","volume":"57","author":"C Knauf","year":"2008","unstructured":"Knauf C, Cani PD, Kim D-H, Iglesias MA, Chabo C, Waget A, et al. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes. 2008;57(10):2603\u201312.","journal-title":"Diabetes"},{"issue":"5","key":"115_CR58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1210\/er.22.5.565","volume":"22","author":"P Gilon","year":"2001","unstructured":"Gilon P, Henquin J-C. Mechanisms and physiological significance of the cholinergic control of pancreatic {beta}-cell function. Endocr Rev. 2001;22(5):565\u2013604.","journal-title":"Endocr Rev"},{"issue":"4","key":"115_CR59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s001250051322","volume":"43","author":"B Ahr\u00e9n","year":"2000","unstructured":"Ahr\u00e9n B. Autonomic regulation of islet hormone secretion\u2014implications for health and disease. Diabetologia. 2000;43(4):393\u2013410.","journal-title":"Diabetologia"},{"issue":"1","key":"115_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2012.11.006","volume":"42","author":"MA Osundiji","year":"2013","unstructured":"Osundiji MA, Evans ML. Brain control of insulin and glucagon secretion. Endocrinol Metab Clin North Am. 2013;42(1):1\u201314.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"Suppl. 3","key":"115_CR61","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1262-3636(10)70468-7","volume":"36","author":"R Burcelin","year":"2010","unstructured":"Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab. 2010;36(Suppl. 3):S54\u20138.","journal-title":"Diabetes Metab"},{"issue":"6","key":"115_CR62","doi-asserted-by":"crossref","first-page":"E996","DOI":"10.1152\/ajpendo.1999.277.6.E996","volume":"277","author":"B Ahren","year":"1999","unstructured":"Ahren B, Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab. 1999;277(6):E996\u20131004.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"115_CR63","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357.","journal-title":"Gastroenterology"},{"issue":"1","key":"115_CR64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1471-4159.2011.07563.x","volume":"121","author":"K Fujiwara","year":"2012","unstructured":"Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T, et al. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J Neurochem. 2012;121(1):66\u201376.","journal-title":"J Neurochem"},{"issue":"8","key":"115_CR65","doi-asserted-by":"crossref","first-page":"R807","DOI":"10.1152\/ajpregu.00276.2012","volume":"303","author":"CB Blake","year":"2012","unstructured":"Blake CB, Smith BN. Insulin reduces excitation in gastric-related neurons of the dorsal motor nucleus of the vagus. Am J Physiol Regul Integr Comp Physiol. 2012;303(8):R807\u201314.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"115_CR66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.brainres.2006.06.109","volume":"1112","author":"AW Pardini","year":"2006","unstructured":"Pardini AW, Nguyen HT, Figlewicz DP, Baskin DG, Williams DL, Kim F, et al. Distribution of insulin receptor substrate-2 in brain areas involved in energy homeostasis. Brain Res. 2006;1112(1):169\u201378.","journal-title":"Brain Res"},{"issue":"3","key":"115_CR67","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0306-4522(91)90049-T","volume":"42","author":"JW Unger","year":"1991","unstructured":"Unger JW, Moss AM, Livingston JN. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience. 1991;42(3):853\u201361.","journal-title":"Neuroscience"},{"issue":"9","key":"115_CR68","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.nut.2008.06.023","volume":"24","author":"SP Kalra","year":"2008","unstructured":"Kalra SP. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: New therapeutic approaches. Nutrition. 2008;24(9):820\u20136.","journal-title":"Nutrition"},{"issue":"5708","key":"115_CR69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.1104344","volume":"307","author":"MW Schwartz","year":"2005","unstructured":"Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science. 2005;307(5708):375\u20139.","journal-title":"Science"},{"issue":"1","key":"115_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2003.08.042","volume":"481","author":"SJ Konturek","year":"2003","unstructured":"Konturek SJ, Zabielski R, Konturek JW, Czarnecki J. Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion. Eur J Pharmacol. 2003;481(1):1\u201314.","journal-title":"Eur J Pharmacol"},{"key":"115_CR71","volume-title":"Lectures on conditioned reflexes","author":"I Pavlov","year":"1941","unstructured":"Pavlov I. Lectures on conditioned reflexes. 3rd ed. London: Lawrence and Wishart; 1941.","edition":"3"},{"key":"115_CR72","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1152\/ajplegacy.1969.216.6.1496","volume":"216","author":"LA Frohman","year":"1969","unstructured":"Frohman LA, Bernardis LL, Schnatz JD, Burek L. Plasma insulin and triglyceride levels after hypothalamic lesions in weanling rats. Am J Physiol. 1969;216:1496\u2013501.","journal-title":"Am J Physiol"},{"key":"115_CR73","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1042\/bj0900620","volume":"90","author":"CN Hales","year":"1964","unstructured":"Hales CN, Kennedy GC. Plasma glucose, nonesterified fatty acid and insulin concentrations in hypothalamic-hyperphagia rats. Biochem J. 1964;90:620\u20134.","journal-title":"Biochem J"},{"key":"115_CR74","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1172\/JCI109744","volume":"65","author":"F Rohner-Jeanrenaud","year":"1980","unstructured":"Rohner-Jeanrenaud F, Jeanrenaud B. Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat. J Clin Invest. 1980;65:902\u201310.","journal-title":"J Clin Invest"},{"key":"115_CR75","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1210\/endo-105-1-146","volume":"105","author":"H-R Berthoud","year":"1979","unstructured":"Berthoud H-R, Jeanrenaud B. Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology. 1979;105:146\u201351.","journal-title":"Endocrinology"},{"key":"115_CR76","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00254511","volume":"20","author":"DA Bereiter","year":"1981","unstructured":"Bereiter DA, Rohner-Jeanrenaud F, Berthoud H-R, Jeanrenaud B. CNS modulation of pancreatic endocrine function. Diabetologia. 1981;20:417\u201325.","journal-title":"Diabetologia"},{"issue":"5","key":"115_CR77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2826.2004.01185.x","volume":"16","author":"E Guillod-Maximin","year":"2004","unstructured":"Guillod-Maximin E, Lorsignol A, Alquier T, P\u00e9nicaud L. Acute intracarotid glucose injection towards the brain induces specific c-fos activation in hypothalamic nuclei: involvement of astrocytes in cerebral glucose-sensing in rats. J Neuroendocrinol. 2004;16(5):464\u201371.","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"115_CR78","doi-asserted-by":"crossref","first-page":"E436","DOI":"10.1152\/ajpendo.00538.2001","volume":"283","author":"P-Q Yuan","year":"2002","unstructured":"Yuan P-Q, Yang H. Neuronal activation of brain vagal-regulatory pathways and upper gut enteric plexuses by insulin hypoglycemia. Am J Physiol Endocrinol Metab. 2002;283(3):E436\u201348.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"115_CR79","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nm0603-645","volume":"9","author":"JK Elmquist","year":"2003","unstructured":"Elmquist JK, Marcus JN. Rethinking the central causes of diabetes. Nat Med. 2003;9(6):645\u20137.","journal-title":"Nat Med"},{"key":"115_CR80","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nm873","volume":"9","author":"S Obici","year":"2003","unstructured":"Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9:756\u201361.","journal-title":"Nat Med"},{"issue":"6","key":"115_CR81","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nn0602-861","volume":"5","author":"S Obici","year":"2002","unstructured":"Obici S, Feng Z, Karkanias G, Baskin D, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci. 2002;5(6):566\u201372.","journal-title":"Nat Neurosci"},{"key":"115_CR82","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1172\/JCI200114127","volume":"108","author":"MW Schwartz","year":"2001","unstructured":"Schwartz MW. Progress in the search for neuronal mechanisms coupling type 2 diabetes to obesity. J Clin Invest. 2001;108:963\u20134.","journal-title":"J Clin Invest"},{"issue":"1","key":"115_CR83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2012.11.001","volume":"42","author":"R Rodriguez-Diaz","year":"2013","unstructured":"Rodriguez-Diaz R, Caicedo A. Novel approaches to studying the role of innervation in the biology of pancreatic islets. Endocrinol Metab Clin North Am. 2013;42(1):39\u201356.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"115_CR84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0149-7634(95)00040-L","volume":"20","author":"RC Rogers","year":"1996","unstructured":"Rogers RC, McTigue DM, Hermann GE. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev. 1996;20(1):57\u201366.","journal-title":"Neurosci Biobehav Rev"},{"key":"115_CR85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.physiol.68.040504.094635","volume":"68","author":"RA Travagli","year":"2006","unstructured":"Travagli RA, Hermann GE, Browning KN, Rogers RC. Brainstem circuits regulating gastric function. Annu Rev Physiol. 2006;68:279\u2013305.","journal-title":"Annu Rev Physiol"},{"issue":"1\u20132","key":"115_CR86","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2008.10.010","volume":"206","author":"F Wuchert","year":"2009","unstructured":"Wuchert F, Ott D, Rafalzik S, Roth J, Gerstberger R. Tumor necrosis factor-[alpha], interleukin-1[beta] and nitric oxide induce calcium transients in distinct populations of cells cultured from the rat area postrema. J Neuroimmunol. 2009;206(1\u20132):44\u201351.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"115_CR87","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0196-9781(86)90234-2","volume":"7","author":"TS Gray","year":"1986","unstructured":"Gray TS, O\u2019Donohue TL, Magnuson DJ. Neuropeptide Y innervation of amygdaloid and hypothalamic neurons that project to the dorsal vagal complex in rat. Peptides. 1986;7(2):341\u20139.","journal-title":"Peptides"},{"issue":"2\u20133","key":"115_CR88","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.regpep.2006.02.005","volume":"134","author":"Z Hou","year":"2006","unstructured":"Hou Z, Miao Y, Gao L, Pan H, Zhu S. Ghrelin-containing neuron in cerebral cortex and hypothalamus linked with the DVC of brainstem in rat. Regul Pept. 2006;134(2\u20133):126\u201331.","journal-title":"Regul Pept"},{"issue":"4","key":"115_CR89","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1152\/jn.00791.2003","volume":"91","author":"X Wu","year":"2004","unstructured":"Wu X, Gao J, Yan J, Owyang C, Li Y. Hypothalamus\u2013brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat. J Neurophysiol. 2004;91(4):1734\u201347.","journal-title":"J Neurophysiol"},{"issue":"1","key":"115_CR90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah H. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27\u201335.","journal-title":"Mol Psychiatry"},{"key":"115_CR91","doi-asserted-by":"crossref","unstructured":"Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010(11):CD006633.","DOI":"10.1002\/14651858.CD006633.pub2"},{"issue":"7","key":"115_CR92","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","volume":"27","author":"S Kapur","year":"2003","unstructured":"Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081\u201390.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Supplement 2","key":"115_CR93","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","volume":"25","author":"CU Correll","year":"2010","unstructured":"Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Supplement 2):S12\u201321.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"115_CR94","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/14737175.9.1.73","volume":"9","author":"E Scarr","year":"2009","unstructured":"Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother. 2009;9(1):73\u201386.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"115_CR95","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","volume":"50","author":"MP Caulfield","year":"1998","unstructured":"Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279\u201390.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"115_CR96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jnr.20600","volume":"81","author":"C Deng","year":"2005","unstructured":"Deng C, Huang X-F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res. 2005;81(6):883\u201390.","journal-title":"J Neurosci Res"},{"issue":"4","key":"115_CR97","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S1472928803120018","volume":"2","author":"B Dean","year":"2004","unstructured":"Dean B, Gray L, Keriakous D, Scarr E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Relat Syst. 2004;2(4):287\u201395.","journal-title":"Thalamus Relat Syst"},{"issue":"11","key":"115_CR98","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mp.2008.28","volume":"14","author":"E Scarr","year":"2008","unstructured":"Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. 2008;14(11):1017\u201323.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"115_CR99","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopsych.2006.08.050","volume":"61","author":"E Scarr","year":"2007","unstructured":"Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but Not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry. 2007;61(10):1161\u201370.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"115_CR100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","volume":"12","author":"TJ Raedler","year":"2006","unstructured":"Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2006;12(3):232\u201346.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"115_CR101","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.pnpbp.2007.02.009","volume":"31","author":"C Deng","year":"2007","unstructured":"Deng C, Weston-Green KL, Han M, Huang X-F. Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):915\u201320.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"115_CR102","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lfs.2005.06.038","volume":"78","author":"E Scarr","year":"2006","unstructured":"Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTP[gamma]S binding in schizophrenia. Life Sci. 2006;78(11):1231\u20137.","journal-title":"Life Sci"},{"key":"115_CR103","doi-asserted-by":"crossref","unstructured":"Steward LJ, Kennedy MD, Morris BJ, Pratt JA. Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain : Impact of antipsychotic drug treatment. Neuropharmacology. 2012;62(3):1554\u201363.","DOI":"10.1016\/j.neuropharm.2011.05.016"},{"issue":"Suppl 1","key":"115_CR104","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1038\/sj.mp.4001019","volume":"7","author":"F Bymaster","year":"2002","unstructured":"Bymaster F, Felder C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol Psychiatry. 2002;7(Suppl 1):S57\u201363.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"115_CR105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/01.jcp.0000239789.83707.7d","volume":"26","author":"R Jindal","year":"2006","unstructured":"Jindal R, Keshavan M. Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. J Clin Psychopharmacol. 2006;26(5):449\u201350.","journal-title":"J Clin Psychopharmacol"},{"issue":"20","key":"115_CR106","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1359-6446(05)03630-5","volume":"10","author":"MF O\u2019Neill","year":"2005","unstructured":"O\u2019Neill MF. Unusual suspect for antipsychotic-induced diabetes. Drug Discov Today. 2005;10(20):1338.","journal-title":"Drug Discov Today"},{"issue":"1","key":"115_CR107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","volume":"125","author":"GP Reynolds","year":"2010","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169\u201379.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"115_CR108","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","volume":"24","author":"FCJ Starrenburg","year":"2009","unstructured":"Starrenburg FCJ, Bogers JPAM. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009;24(3):164\u201370.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"115_CR109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","volume":"27","author":"J Silvestre","year":"2005","unstructured":"Silvestre J, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289\u2013304.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"5","key":"115_CR110","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","volume":"20","author":"A Matsui-Sakata","year":"2005","unstructured":"Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368\u201378.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"115_CR111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00561782","volume":"11","author":"G Erle","year":"1977","unstructured":"Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol. 1977;11(1):15\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"115_CR112","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0006-2952(01)00786-9","volume":"62","author":"J Bhattacharyya","year":"2001","unstructured":"Bhattacharyya J, Das KP. Aggregation of insulin by chlorpromazine. Biochem Pharmacol. 2001;62(9):1293\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"115_CR113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)29688-4","volume":"187","author":"HPT Ammon","year":"1973","unstructured":"Ammon HPT, Orci L, Steinke J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther. 1973;187(2):423\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"26","key":"115_CR114","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.lfs.2007.04.001","volume":"80","author":"S Park","year":"2007","unstructured":"Park S, Hong SM, Lee JE, Sung SR. Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects. Life Sci. 2007;80(26):2428\u201335.","journal-title":"Life Sci"},{"issue":"1","key":"115_CR115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0306-4522(94)90017-5","volume":"63","author":"AI Levey","year":"1994","unstructured":"Levey AI, Edmunds SM, Heilman CJ, Desmond TJ, Frey KA. Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain. Neuroscience. 1994;63(1):207\u201321.","journal-title":"Neuroscience"},{"issue":"1","key":"115_CR116","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0022-3565(25)10285-1","volume":"264","author":"JK Zubieta","year":"1993","unstructured":"Zubieta JK, Frey KA. Autoradiographic mapping of M3 muscarinic receptors in the rat brain. J Pharmacol Exp Ther. 1993;264(1):415\u201322.","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"115_CR117","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1073\/pnas.0900977106","volume":"106","author":"D Gautam","year":"2009","unstructured":"Gautam D, Jeon J, Starost MF, Han S-J, Hamdan FF, Cui Y, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci. 2009;106(15):6398\u2013403.","journal-title":"Proc Natl Acad Sci"},{"issue":"1\u20133","key":"115_CR118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejphar.2009.01.047","volume":"608","author":"S Balakrishnan","year":"2009","unstructured":"Balakrishnan S, Mathew J, Antony S, Paulose CS. Muscarinic M1, M3 receptors function in the brainstem of streptozotocin induced diabetic rats: their role in insulin secretion from the pancreatic islets as a function of age. Eur J Pharmacol. 2009;608(1\u20133):14\u201322.","journal-title":"Eur J Pharmacol"},{"issue":"19","key":"115_CR119","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.lfs.2004.03.034","volume":"75","author":"TR Renuka","year":"2004","unstructured":"Renuka TR, Ani DV, Paulose CS. Alterations in the muscarinic M1 and M3 receptor gene expression in the brain stem during pancreatic regeneration and insulin secretion in weanling rats. Life Sci. 2004;75(19):2269\u201380.","journal-title":"Life Sci"},{"issue":"1","key":"115_CR120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1423-0127-17-7","volume":"17","author":"S Antony","year":"2010","unstructured":"Antony S, Kumar TP, Mathew J, Anju TR, Paulose CS. Hypoglycemia induced changes in cholinergic receptor expression in the cerebellum of diabetic rats. J Biomed Sci. 2010;17(1):7.","journal-title":"J Biomed Sci"},{"issue":"10","key":"115_CR121","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","volume":"59","author":"PJF Martins","year":"2010","unstructured":"Martins PJF, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes. 2010;59(10):2418\u201325.","journal-title":"Diabetes"},{"issue":"5","key":"115_CR122","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2011.09.003","volume":"22","author":"K Weston-Green","year":"2012","unstructured":"Weston-Green K, Huang X-F, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012;22(5):364\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"115_CR123","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1152\/advan.00167.2012","volume":"37","author":"DP Begg","year":"2013","unstructured":"Begg DP, Woods SC. Interactions between the central nervous system and pancreatic islet secretions: a historical perspective. Adv Physiol Educ. 2013;37(1):53\u201360.","journal-title":"Adv Physiol Educ"},{"issue":"4","key":"115_CR124","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/1096-9861(20010319)431:4<405::AID-CNE1079>3.0.CO;2-D","volume":"431","author":"R Buijs","year":"2001","unstructured":"Buijs R, Chun S, Niijima A, Romijn H, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol. 2001;431(4):405\u201323.","journal-title":"J Comp Neurol"},{"issue":"2","key":"115_CR125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tem.2010.10.004","volume":"22","author":"I Ruiz de Azua","year":"2011","unstructured":"Ruiz de Azua I, Gautam D, Guettier J-M, Wess J. Novel insights into the function of [beta]-cell M3 muscarinic acetylcholine receptors: therapeutic implications. Trends Endocrinol Metabol. 2011;22(2):74\u201380.","journal-title":"Trends Endocrinol Metabol"},{"issue":"12","key":"115_CR126","doi-asserted-by":"crossref","first-page":"G1117","DOI":"10.1152\/ajpgi.00035.2013","volume":"304","author":"A Plamboeck","year":"2013","unstructured":"Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol. 2013;304(12):G1117\u201327.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"115_CR127","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.physbeh.2009.01.009","volume":"97","author":"GJ Dockray","year":"2009","unstructured":"Dockray GJ. The versatility of the vagus. Physiol Behav. 2009;97(5):531\u20136.","journal-title":"Physiol Behav"},{"issue":"1\u20133","key":"115_CR128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.regpep.2007.08.024","volume":"149","author":"H-R Berthoud","year":"2008","unstructured":"Berthoud H-R. The vagus nerve, food intake and obesity. Regul Pept. 2008;149(1\u20133):15\u201325.","journal-title":"Regul Pept"},{"issue":"16","key":"115_CR129","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.lfs.2005.04.006","volume":"77","author":"Y Ochi","year":"2005","unstructured":"Ochi Y, Horie S, Maruyama T, Watanabe K, Yano S. Necessity of intracellular cyclic AMP in inducing gastric acid secretion via muscarinic M3 and cholecystokinin2 receptors on parietal cells in isolated mouse stomach. Life Sci. 2005;77(16):2040\u201350.","journal-title":"Life Sci"},{"issue":"11","key":"115_CR130","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1210\/en.2010-0519","volume":"151","author":"D Gautam","year":"2010","unstructured":"Gautam D, de Azua IR, Li JH, Guettier J-M, Heard T, Cui Y, et al. Beneficial metabolic effects caused by persistent activation of {beta}-cell M3 muscarinic acetylcholine receptors in transgenic mice. Endocrinology. 2010;151(11):5185\u201394.","journal-title":"Endocrinology"},{"issue":"5","key":"115_CR131","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2006.09.008","volume":"4","author":"D Gautam","year":"2006","unstructured":"Gautam D, Gavrilova O, Jeon J, Pack S, Jou W, Cui Y, et al. Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency. Cell Metab. 2006;4(5):363\u201375.","journal-title":"Cell Metab"},{"issue":"6","key":"115_CR132","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cmet.2006.04.009","volume":"3","author":"D Gautam","year":"2006","unstructured":"Gautam D, Han S-J, Hamdan FF, Jeon J, Li B, Li JH, et al. A critical role for [beta] cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 2006;3(6):449\u201361.","journal-title":"Cell Metab"},{"issue":"6","key":"115_CR133","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2006.05.004","volume":"3","author":"J Gromada","year":"2006","unstructured":"Gromada J, Hughes TE. Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic [beta] cell function. Cell Metab. 2006;3(6):390\u20132.","journal-title":"Cell Metab"},{"issue":"4","key":"115_CR134","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbrc.2004.01.139","volume":"315","author":"WS Zawalich","year":"2004","unstructured":"Zawalich WS, Zawalich KC, Tesz GJ, Taketo MM, Sterpka J, Philbrick W, et al. Effects of muscarinic receptor type 3 knockout on mouse islet secretory responses. Biochem Biophys Res Commun. 2004;315(4):872\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6825","key":"115_CR135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35065604","volume":"410","author":"M Yamada","year":"2001","unstructured":"Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature. 2001;410(6825):207\u201312.","journal-title":"Nature"},{"key":"115_CR136","doi-asserted-by":"crossref","unstructured":"Ruiz de Azua I, Gautam D, Jain S, Guettier J-M, Wess Jr. Critical metabolic roles of \u03b2-cell M3 muscarinic acetylcholine receptors. Life Sci. 2012;91(21\u201322):986\u201391.","DOI":"10.1016\/j.lfs.2012.04.010"},{"key":"115_CR137","doi-asserted-by":"crossref","unstructured":"Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8(5):369\u201385.","DOI":"10.1038\/nrd2782"},{"key":"115_CR138","doi-asserted-by":"crossref","unstructured":"Kong KC, Butcher AJ, McWilliams P, Jones D, Wess Jr, Hamdan FF et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation\/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci USA. 2010;107(49):21181\u20136.","DOI":"10.1073\/pnas.1011651107"},{"issue":"7","key":"115_CR139","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/diabetes.53.7.1714","volume":"53","author":"A Duttaroy","year":"2004","unstructured":"Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in M3 muscarinic acetylcholine receptor-deficient mice. Diabetes. 2004;53(7):1714\u201320.","journal-title":"Diabetes"},{"issue":"12","key":"115_CR140","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.2337\/db09-0522","volume":"58","author":"JH Li","year":"2009","unstructured":"Li JH, Gautam D, Han SJ, Guettier JM, Cui Y, Lu H, et al. Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice. Diabetes. 2009;58(12):2776\u201387.","journal-title":"Diabetes"},{"issue":"2","key":"115_CR141","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1152\/ajpendo.1995.268.2.E336","volume":"268","author":"AC Boschero","year":"1995","unstructured":"Boschero AC, Szpak-Glasman M, Carneiro EM, Bordin S, Paul I, Rojas E, et al. Oxotremorine-m potentiation of glucose-induced insulin release from rat islets involves M3 muscarinic receptors. Am J Physiol Endocrinol Metab. 1995;268(2):E336\u201342.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"115_CR142","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0197-0186(93)90051-6","volume":"22","author":"D Collins","year":"1993","unstructured":"Collins D, Smith DA, Messer WS Jr. Regional binding of 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP) to muscarinic receptors in rat brain and comparative analysis of minimum energy conformations. Neurochem Int. 1993;22(3):237\u201347.","journal-title":"Neurochem Int"},{"key":"115_CR143","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","volume":"131","author":"M Hahn","year":"2011","unstructured":"Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011;131:90\u20135.","journal-title":"Schizophr Res"},{"issue":"2","key":"115_CR144","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lfs.2006.08.028","volume":"80","author":"S Yamada","year":"2006","unstructured":"Yamada S, Maruyama S, Takagi Y, Uchida S, Oki T. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci. 2006;80(2):127\u201332.","journal-title":"Life Sci"},{"issue":"2","key":"115_CR145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2012","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114\u201326.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"115_CR146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-013-2982-3","volume":"226","author":"M Guenette","year":"2013","unstructured":"Guenette M, Hahn M, Cohn T, Teo C, Remington G. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 2013;226(1):1\u201312.","journal-title":"Psychopharmacology"},{"issue":"3","key":"115_CR147","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"115_CR148","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 2000;68(1):29\u201339.","journal-title":"Life Sci"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0115-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0115-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T12:22:26Z","timestamp":1746015746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0115-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,10]]},"references-count":148,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0115-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,10]]}}}